Search results
Author(s):
Martin B Leon
Added:
4 months ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic…
View more
Author(s):
Nils Perrin
,
Anita W Asgar
Added:
2 years ago
Corrado Tamburino
Job title: Professor and Chief of Cardiothoracic, Transplantation and Vascular Surgery Department
Author
Author(s):
David J Cohen
Added:
2 years ago
Dr David J Cohen (St Francis Hospital, Roslyn, NY, US) discusses the findings from PARTNER 3 Economic Study. The study, presented first at TCT 2021, showed that for patients with severe AS and low surgical risk, TF-TAVR with the SAPIEN 3 valve is cost-saving compared with SAVR at 2-year follow-up.
Discussion Points
Importance of the Study
Used Data
Complexities in Relation to the Costs of…
View more
Author(s):
Raj Makkar
Added:
5 months ago
In this insightful interview, investigator, Prof Raj R Makkar(Cedars-Sinai Heart Institute, US) joins us to discuss the outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves.
Prof Makkar and his team used the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry to address a series of questions regarding the safety…
View more
TCT 23: EVOLUT Low-Risk
Author(s):
Michael J Reardon
Added:
5 months ago
Video
Author(s):
Sahoor Khan
,
William Shi
,
Tsuyoshi Kaneko
,
et al
Added:
1 year ago
Author(s):
Quynh Nguyen
,
Jessica GY Luc
,
Thomas E MacGillivray
,
et al
Added:
1 year ago
Author(s):
Anne H Tavenier
,
Johny Nicolas
,
Roxana Mehran
Added:
1 year ago
Who should be referred for TAVR?
Author(s):
Colin M Barker
,
Michael J Reardon
Added:
3 years ago
Article